MAPT and Alzheimer disease: Moreover, gene expression changes observed in astrocytes isolated from the GFAP-Nrf2 mouse were enriched in genes induced by both Tau and Aß pathology, as well as in genes induced in human PM AD astrocytes, pointing to Nrf2 activation being evident in response to AD-relevant pathology, and consistent with prior studies showing astrocytic Nrf2 target gene induction in AD (and MCI) patients61,62.